Dr. Shin Mukai, PhD is a highly accomplished chemical biologist with over 20 years of experience in the field. He received his Bachelor's degree in Chemistry from Kyoto University, followed by a Master's degree and PhD in Bio-Organic Chemistry from Kyoto University and the University of Western Australia, respectively. After completing his education, Dr. Mukai worked as a Postdoctoral Research Fellow at Keio University School of Medicine and Brigham and Women's Hospital / Harvard Medical School. During this time, he conducted groundbreaking research in the areas of drug discovery and development, focusing on novel treatments for various diseases. In 2022, Dr. Mukai joined Sanofi as a Scientist III, where he continued his research in drug discovery and development. He opened a new avenue for biology in human B-cells, eosinophills, neutrophils and mast cells, making significant contributions to the field. In 2023, Dr. Mukai co-founded New Wind Therapeutics L3C, a pharmaceutical company that focuses on discovering and developing new small-molecule drugs for the treatment of pancreatic cancer. As the Chief Executive Officer and Chief Scientific Officer, he oversees the company's research and development efforts, utilizing his extensive knowledge and expertise in organic/medicinal chemistry, biology and immunology. Dr. Mukai has published numerous research papers in top scientific journals and has received several awards and honors for his work. He is highly respected in the scientific community and continues to make significant contributions to the field of chemical biology.